Latest Regulatory Approval News

Power Minerals confirms a high-grade carbonatite hard rock intrusion at its Santa Anna Rare Earth Elements Project in Brazil, with promising grades and ongoing drilling aimed at defining a maiden resource estimate.

Aquirian Limited reports a 16.7% revenue increase alongside key operational advances at its Wubin facility and new leadership appointments, signaling strong momentum in mining services and technology.

TPC Consolidated and Wollar Solar Holding have agreed to extend key deadlines in their acquisition scheme as they await crucial FIRB approval, pushing the timeline into early 2026.

Altamin Limited has initiated a 45 for 100 accelerated pro-rata entitlement offer at $0.025 per share to raise up to AUD 6.46 million, supporting its Lazio and Gorno projects in Italy. The offer includes a strong institutional backing and opens to eligible retail shareholders across multiple jurisdictions.

ReNerve Ltd is rapidly advancing its nerve repair product portfolio, with four ranges expected on the market by the end of 2025 and expanding global distribution. Clinical studies highlight significant patient benefits, supporting the company’s growth in a booming biomaterials market.

Rimfire Pacific Mining is set to begin a fully funded 24-hole drilling campaign at its Rabbit Trap Scandium Project in central New South Wales, targeting promising laterite-hosted scandium mineralisation.

Reef Casino Trust (ASX, RCT) has received a recommended off-market takeover offer from Iris Cairns Property Pty Ltd at $3.87 per unit, representing a significant premium over recent trading prices. The independent expert affirms the offer as fair and reasonable, with major unitholders supporting the bid subject to regulatory approvals.

Redcastle Resources and BML advance their strategic gold joint venture with key studies completed and mining proposal submission expected by late 2025, targeting initial production in early 2026.

Island Pharmaceuticals has submitted a detailed briefing to the FDA aiming to accelerate approval of its antiviral Galidesivir for Marburg virus under the Animal Rule, with feedback expected by November.

EMVision Medical Devices launches a $2 million Share Purchase Plan offering shares at a 16.4% discount, bundled with free options exercisable at $3.40, aiming to bolster clinical and commercial milestones.

Synlait Milk Limited reports a modest profit turnaround in FY25 and announces a major sale of its North Island assets to Abbott, aiming to reduce debt and sharpen its focus on core operations.

Synlait has agreed to sell its North Island assets to global healthcare giant Abbott for approximately US$178 million, marking a strategic reset focused on debt reduction and operational simplification. The deal, expected to close by April 2026, positions Synlait to concentrate on its South Island operations and explore new growth avenues.